vTv Therapeutics Stock Forecast, Price & News

Wall Street analysts have given vTv Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but vTv Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

vTv Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for vTv Therapeutics.

vTv Therapeutics Inc. (NASDAQ:VTVT) released its quarterly earnings data on Wednesday, May, 5th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.03. The biotechnology company earned $0.99 million during the quarter, compared to analyst estimates of $0.80 million.
View vTv Therapeutics' earnings history.

vTv Therapeutics' stock was trading at $2.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VTVT shares have increased by 1.2% and is now trading at $2.46.
View which stocks have been most impacted by COVID-19.

Some companies that are related to vTv Therapeutics include Affimed (AFMD), Karyopharm Therapeutics (KPTI), Collegium Pharmaceutical (COLL), Sesen Bio (SESN), Silence Therapeutics (SLN), IDEAYA Biosciences (IDYA), Xenon Pharmaceuticals (XENE), Pharming Group (PHAR), Cara Therapeutics (CARA), KalVista Pharmaceuticals (KALV), Ardelyx (ARDX), Crinetics Pharmaceuticals (CRNX), Calliditas Therapeutics AB (publ) (CALT), Kadmon (KDMN) and Bicycle Therapeutics (BCYC).
View all of VTVT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), (CGC), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA).

(VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

vTv Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Nuveen Asset Management LLC (0.92%), BlackRock Inc. (0.59%), Ensign Peak Advisors Inc (0.40%), Geode Capital Management LLC (0.33%), Citadel Advisors LLC (0.22%) and Northern Trust Corp (0.20%). Company insiders that own vTv Therapeutics stock include Hersh Kozlov and Ronald O Perelman.
View institutional ownership trends for vTv Therapeutics.

VTVT stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund.
View insider buying and selling activity for vTv Therapeutics or view top insider-selling stocks.

VTVT stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Citadel Advisors LLC, Ensign Peak Advisors Inc, Cim Investment Mangement Inc., Geode Capital Management LLC, Citizens Financial Group Inc RI, Goldman Sachs Group Inc., and BlackRock Inc.. Company insiders that have bought vTv Therapeutics stock in the last two years include Hersh Kozlov, and Ronald O Perelman.
View insider buying and selling activity for vTv Therapeutics or or view top insider-buying stocks.

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VTVT stock can currently be purchased for approximately $2.46.

vTv Therapeutics has a market capitalization of $199.52 million and generates $6.41 million in revenue each year. The biotechnology company earns $-8,500,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

vTv Therapeutics employs 25 workers across the globe.

The official website for vTv Therapeutics is www.vtvtherapeutics.com.

vTv Therapeutics is headquartered at 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265.

vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]